Liver, breast, intestinal, and pancreatic cancers as well as common male and female reproductive cancers, have clinically significant tumor markers used to monitor disease progression. Enzyme immunoassays (EIAs) are the gold standard technology used for the quantitative determination of tumor markers including AFP, CA-125, CA15-3, CA19-9, CEA, PSA and Free PSA.